Biogen talks up approval plans for controversial Alzheimer’s drug as it nears FDA decision
April 22, 2021 at 12:36 PM EDT
Biogen Inc.'s first-quarter earnings beat expectations, but investors may be paying more attention to the latest information the company is sharing about its plans for aducanumab, the experimental Alzheimer’s disease drug that has sent the stock on a wild ride.